{'fraction_non_alphanumeric': 0.048597194388777555, 'fraction_numerical': 0.022688233610077296, 'mean_word_length': 4.999570631172177, 'pattern_counts': {'":': 0, '<': 16, '<?xml version=': 0, '>': 2, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Influence of Microalbuminuria on Long-Term Survival and Cardiovascular or Limb Events in Peripheral Arterial Disease

Objective: This study aimed to examine the relationship between microalbuminuria and long-term life expectancy or limb events in patients with peripheral arterial disease (PAD). Materials and Methods: A prospective cohort study was performed in 714 patients with PAD. The primary outcomes were cardiovascular or cerebrovascular death (CCVD) and all-cause death (AD), and secondary outcomes were major adverse cardiovascular events (MACE) and cardiovascular and/or limb events (CVLE). Results: The 5, 10, and 15 year survival rates were 82.4%, 53.1%, and 33.0%, respectively. The prevalence of patients with increased microalbuminuria was 39.2%. Higher microalbuminuria, age, C-reactive protein (CRP), lower serum albumin, estimated glomerular filtration rate (eGFR), ankle–brachial pressure index (ABI), diabetes, cerebral infarction, and coronary heart disease (CHD) were associated with CCVD; higher microalbuminuria, age, CRP, D-dimer, lower serum albumin, eGFR, and critical limb ischemia were related to AD; higher microalbuminuria, age, CRP, lower serum albumin, ABI, diabetes, and CHD were related to MACE; higher microalbuminuria, age, lower ABI, cerebral infarction, and CHD were related to CVLE in Cox multivariate analyses (p<0.05). Statins reduced CCVD, AD, MACE, and CVLE (p<0.001). Conclusion: Higher microalbuminuria was a significant predictor for CCVD, AD, MACE, and CVLE in PAD patients.


Introduction
Peripheral arterial disease (PAD) has been associated with reduced survival because of coronary heart disease (CHD) and cerebral infarction. [1][2][3][4][5] PAD is frequently associated with chronic kidney disease (CKD), [6][7][8] which is a risk factor for cardiovascular disease and stroke. 6,9) Moreover, increased urinary level of microalbumin (MA) is related to a higher risk of CHD and cardiovascular morbidity. 10) In patients with established heart failure, reduced estimated glomerular filtration rate (eGFR) and increased urinary MA are independent predictors for heart failure progression and mortality. 11) Hence, CKD is classified on the basis of Cause, eGFR categories, and Albuminuria categories, abbreviated as CGA categories. 12) However, long-term cardiovascular or all-cause mortality and cardiovascular or limb event related to the urinary level of MA have not been examined clearly in PAD patients. In the present study, we analyzed the relationship between microalbuminuria and long-term life expectancy or leg event in patients with PAD.

Subjects
A total of 725 patients with PAD at the Cardiovascular Hospital of Central Japan were recruited from February 1, 2000, and January 31, 2021. Before initiation, the study protocol was approved by the Medical Ethical Committee of our hospital (CCJ-EA-006), and the study was conducted according to the Declaration of Helsinki. The patients received a full explanation of the study and gave written informed consent. The criteria used for PAD included an ankle-brachial pressure index (ABI) of <0.90, clinical symptoms, and iliac or femoropopliteal artery stenosis of ≥70% defined with ultrasound or angiography. Patients with nephrosis syndrome or those on hemodialysis were excluded from this study.

Baseline patient characteristics
Baseline clinical characteristics for each patient included age, body mass index (BMI), ABI, smoking history, diabetes mellitus (fasting plasma glucose level of >126 mg/dL at least two measurements or a requirement for antidiabetic therapy), and hypertension (receiving oral therapy or blood pressure ≥140/90 mmHg recorded at least twice). A fasting blood sample was collected to measure serum basic metabolic panels. Moreover, we collected a morning urine sample for urinary albumin and creatinine measures. Urinary albumin concentration was measured via turbidimetric immunological technique (Hitachi 7180 automatic analyzer, Hitachi High-Tech Fielding Co., Tokyo, Japan). The urine albumin/creatinine ratio was calculated as mg/g of creatinine (Cr). Patients with an albumin level of <30 mg/gCr were defined as having normoalbuminuria (A1), those with an albumin level of 30-300 mg/gCr (A2), and those with an albumin level of >300 mg/gCr (A3), according to CGA categories. 12) All assays were performed at the Health Science Research Institute, Inc. (Saitama, Japan).
An electrocardiogram was recorded for each patient. CHD was determined as a positive sign in stress/rest myocardial perfusion scintigraphy or coronary angiography and a history of this treatment. The eGFR was calculated with the Modification of Diet in Renal Disease equation with Cr level. 13)

Endpoints
Each subject was followed up at 1, 2, and 4 months after the procedure and assessed intervals were 4 or 6 months. Medical statuses were evaluated using hospital records and questionnaires for life statuses assessed by the Foot Care Club in our hospital. 3,14,15) The definition of myocardial infarction was described previously. 14,16) Cerebral infarction was determined as the presence of a new focal neurological deficit confirmed with computed tomography or magnetic resonance imaging. Restenosis was determined as a decrease in ABI of ≥0.15 and ≥50% stenosis on ultrasonography or angiography, 14,17) and major amputation was determined as above-the-ankle amputation.
The primary outcomes were cardiovascular or cerebro-vascular death (CCVD) and all-cause death (AD), and secondary outcomes were major adverse cardiovascular events (MACE: AD, nonfatal myocardial or cerebral infarction, or transient ischemic attack) and cardiovascular and/or limb events (CVLE: CCVD, nonfatal myocardial or cerebral infarction, transient ischemic attack, major amputation, or any repeat revascularization for a limb).

Analysis methods
All calculations were performed with IBM SPSS Statistics ver. 25.0 (IBM Corp., Armonk, NY, USA). We used a median (interquartile range) to express continuous variables compared via the Wilcoxon test, and a number (%) to express categorical variables compared via chi-square test. In the follow-up term, the Kaplan-Meier estimates were used to define CCVD, AD, MACE, and CVLE and compared using the log-rank test with Bonferroni correction. In Cox univariate analysis, a hazard ratio and 95% confidence interval were calculated for each factor. In this analysis, risk factors with p<0.05 were used to define significant factors related to outcomes in Cox multivariate analysis. In all analyses, p<0.05 was defined as significant. . In all patients, the 5, 10, and 15 year freedom from AD rates were 82.4%, 53.1%, and 33.0%, respectively. Before patients were separated into two subgroups, the prevalence of urinary MA level of A1, A2, or A3 was 60.8% (n=434), 28.2% (n=201), or 11.1% (n=79), respectively. Table 1 summarizes the baseline clinical characteristics of subjects with normal or increased urinary MA. Patients in A2 or A3 were older; had higher BMI, Creactive protein (CRP), triglyceride, and D-dimer; and had a lower eGFR. The rates of critical limb ischemia (CLI), stroke, hypertension, and diabetes mellitus were higher in A2 or A3.

Factors for CCVD and AD
The 5, 10, and 15 year rates for freedom from CCVD among A1, A2, or A3 with significant differences (p<0.01) are shown in Fig. 1(a). Higher level of urinary MA, age, CRP, D-dimer, lower level of serum albumin, BMI, ABI, Nakashima K, et al. eGFR, CLI, diabetes, cerebral infarction, and CHD were related to CCVD in Cox univariate analysis (Table 2(a), p<0.05). Statin was related to CCVD. Higher urinary level of MA, age, CRP, lower level of serum albumin, eGFR ABI, diabetes, cerebral infarction, and CHD were also associated with CCVD, and statin reduced CCVD in Cox multivariate analysis (p<0.05). The 5, 10, and 15 year rates for freedom from AD among A1, A2, and A3 with significant differences (p<0.05) are shown in Fig. 1(b). Higher level of urinary MA, age, CRP, D-dimer, lower level of serum albumin, BMI, ABI, eGFR, and CLI were related to AD in Cox univariate analysis (Table 2(b), p<0.05). Revascularization, statin, or aspirin was related to AD. Higher urinary level of MA, age, CRP, D-dimer, lower level of serum albumin, eGFR, and CLI were also associated with AD, and statin reduced AD in multivariate analysis (p<0.05).

Factors for MACE and CVLE
The 5, 10, and 15 year rates for freedom from MACE are shown in Fig. 2(a). Significant differences were found between A1 and A3 (p=0.009) and A2 and A3 categories (p=0.039), but there was no significant difference between A1 and A2 categories (p=0.141). Higher level of urinary MA, age, CRP, D-dimer, lower level of serum albumin, BMI, ABI, eGFR, CLI, diabetes, and CHD were related to MACE, and statin therapy was related to MACE significantly in Cox univariate analysis (Table 3(a), p<0.05). Higher level of urinary MA, age, CRP, lower level of serum albumin, ABI, diabetes, and CHD were re-   Fig. 2(b). There were significant differences between A1 and A3 (p<0.001) and A2 and A3 categories (p=0.006), but no significant difference was found between A1 and A2 categories (p=0.126). Higher level of urinary MA, age, CRP, lower level of serum albumin, ABI, eGFR, CLI, diabetes, cerebral infarction, and CHD were related to CVLE, and statin therapy was related to CVLE in Cox univariate analysis (Table 3(b), p<0.05). Higher urinary level of MA, age, lower ABI, cerebral infarction, and CHD were related to CVLE, and statin therapy was also related to CVLE in multivariate analysis (p<0.05). The higher urinary level of MA was a significant factor associated with CVLE in this analysis (p=0.007).

Discussion
Our data represented the first clinical evidence for the relationship between microalbuminuria and long-term life expectancy or leg events in PAD patients. In this study, the prevalence of albuminuria categories (A2 or A3) was 39.2%, and the higher level of urinary MA was a predictive factor for CCVD and AD. In this study, CCVD was correlated with the higher urinary level of MA, age, CRP, lower level of serum albumin, eGFR, ABI, diabetes, cerebral infarction, and CHD. And AD was correlated with the higher urinary level of MA, age, CRP, D-dimer, lower level of serum albumin, eGFR, and CLI. Some studies have reported that CKD is a risk factor for CHD, valvular heart disease, and cerebrovascular disease, 6,9,18) and cardiovascular death is markedly accelerated in patients on hemo-dialysis. 6) Moreover, microalbuminuria is independently related to increased cardiovascular risks and morbidity. 10) We have reported that urinary level of MA is related to low-density lipoprotein cholesterol, age, CHD, CLI, and diabetes in patients with PAD. 8) Hence, CKD is classified on the basis of eGFR categories, and urinary levels of MA are added in CGA categories. 12) CLI and lower ABI are associated with a higher risk of cardiovascular events because of systemic or severe atherosclerosis. 3,19) Cardiovascular and cerebrovascular diseases were major causes of AD. Moreover, malnutrition is a strong risk factor for AD. 3,20) We have reported that the geriatric nutritional risk index is a meaningful predictor for AD, MACE, and major adverse cardiovascular and limb events in PAD patients. 21) These results suggest that patients with lower serum albumin, lower ABI, or CLI have causes of higher mortality based on systemic severe atherosclerosis.
In this study, higher albuminuria was also an independent predictive factor for MACE and CVLE. Higher level of urinary MA, age, CRP, lower level of serum albumin, ABI, diabetes, and CHD were related to MACE, and higher urinary MA level, age, lower ABI, cerebral infarction, and CHD were related to CVLE. Microalbuminuria has been reported to be independently related to increased cardiovascular risk factors and MACE. 10) Moreover, reduced eGFR and albuminuria are independent predictors of heart failure progression and mortality in patients with heart failure. 11) We have reported that cerebral infarction, diabetes, and CKD are predictive risk factors for aggravation of stages of PAD. 15,22) Sensory disturbance, decreased physical faculties, and systemic atherosclerosis may be related to the causes of these outcomes. 1,22) Urinary MA Fig. 2  levels are associated linearly with an increasing likelihood for the presence of PAD, even in the normal range of albuminuria in the Japanese general population. 23) Systemic vascular atherosclerosis reflected by a higher level of urinary MA might be responsible for MACE and CVLE. In this study, a higher level of urinary MA was a significant risk factor associated with CVLE. Hence, higher urinary MA level was related to systemic vascular atherosclerosis including limb vessels in patients with PAD. Statin therapy has an antiatherogenic effect on CHD and reduces MACE. 24,25) Treatments with statins are efficient for improving AD and MACE in PAD patients with or without symptoms detected via the measurements of ABI. 26) However, treatments with statins appear to be less effective in decreasing risks of CHD in patients with CKD and those on hemodialysis treatment. 27,28) Additionally, statins are recommended for all patients with PAD in recent guidelines. 29) Our findings also suggested that statins improve long-term CCVD and AD and decrease the risks of MACE and CVLE in patients with PAD.
The present study had some limitations: 1) the number of patients was relatively small; 2) this study was based on the data from a single institution; 3) a single morning urine sample was used to measure albumin and creatinine levels; 4) the prevalence of CLI was low as a result of the inclusion criteria in which patients on hemodialysis were excluded; and 5) the rate of statin therapy was relatively lower than in the recent guidelines, but the rate has risen over time. These limitations need further study with a larger patient cohort with PAD for CCVD, AD, MACE, and CVLE.